ZA201906873B - Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators - Google Patents
Tetrahydro-benzo[d]azepine derivatives as gpr120 modulatorsInfo
- Publication number
- ZA201906873B ZA201906873B ZA2019/06873A ZA201906873A ZA201906873B ZA 201906873 B ZA201906873 B ZA 201906873B ZA 2019/06873 A ZA2019/06873 A ZA 2019/06873A ZA 201906873 A ZA201906873 A ZA 201906873A ZA 201906873 B ZA201906873 B ZA 201906873B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzo
- tetrahydro
- azepine derivatives
- gpr120 modulators
- gpr120
- Prior art date
Links
- MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical class C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704714.3A GB201704714D0 (en) | 2017-03-24 | 2017-03-24 | Pharmaceutical compounds |
| PCT/GB2018/000047 WO2018172727A1 (en) | 2017-03-24 | 2018-03-26 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201906873B true ZA201906873B (en) | 2022-03-30 |
Family
ID=58687800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/06873A ZA201906873B (en) | 2017-03-24 | 2019-10-18 | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11220483B2 (https=) |
| EP (1) | EP3601229B1 (https=) |
| JP (1) | JP7099672B2 (https=) |
| KR (1) | KR102636166B1 (https=) |
| CN (1) | CN110891938B (https=) |
| AU (1) | AU2018238102B2 (https=) |
| BR (1) | BR112019019868A2 (https=) |
| CA (1) | CA3057415A1 (https=) |
| GB (1) | GB201704714D0 (https=) |
| MX (1) | MX394818B (https=) |
| WO (1) | WO2018172727A1 (https=) |
| ZA (1) | ZA201906873B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
| WO2022076503A1 (en) * | 2020-10-08 | 2022-04-14 | Eli Lilly And Company | 6-methoxy-3,4-dihydro-1h-isoquinoline compounds useful in the treatment of diabetes |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005282721A1 (en) * | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| AU2006279548A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| CA2627682A1 (en) | 2006-01-30 | 2007-08-09 | Irm Llc | Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators |
| ATE528306T1 (de) * | 2006-11-02 | 2011-10-15 | Piramal Life Sciences Ltd | Benzoxazepin-verbindungen, ihre herstellung und verwendung |
| JP2010519258A (ja) | 2007-02-22 | 2010-06-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体 |
| WO2009147990A1 (ja) * | 2008-06-02 | 2009-12-10 | 萬有製薬株式会社 | 新規イソオキサゾール誘導体 |
| EP2736330A4 (en) | 2011-07-29 | 2015-05-27 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| AU2015367977B9 (en) * | 2014-12-24 | 2020-02-06 | Lg Chem, Ltd | Biaryl derivative as GPR120 agonist |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
-
2017
- 2017-03-24 GB GBGB1704714.3A patent/GB201704714D0/en not_active Ceased
-
2018
- 2018-03-26 EP EP18715236.8A patent/EP3601229B1/en active Active
- 2018-03-26 AU AU2018238102A patent/AU2018238102B2/en active Active
- 2018-03-26 JP JP2020501850A patent/JP7099672B2/ja active Active
- 2018-03-26 WO PCT/GB2018/000047 patent/WO2018172727A1/en not_active Ceased
- 2018-03-26 CA CA3057415A patent/CA3057415A1/en active Pending
- 2018-03-26 CN CN201880033700.7A patent/CN110891938B/zh not_active Expired - Fee Related
- 2018-03-26 KR KR1020197031368A patent/KR102636166B1/ko active Active
- 2018-03-26 US US16/496,786 patent/US11220483B2/en active Active
- 2018-03-26 MX MX2019011314A patent/MX394818B/es unknown
- 2018-03-26 BR BR112019019868A patent/BR112019019868A2/pt not_active Application Discontinuation
-
2019
- 2019-10-18 ZA ZA2019/06873A patent/ZA201906873B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3057415A1 (en) | 2018-09-27 |
| AU2018238102A1 (en) | 2019-10-31 |
| AU2018238102B2 (en) | 2021-11-04 |
| KR102636166B1 (ko) | 2024-02-13 |
| JP7099672B2 (ja) | 2022-07-12 |
| JP2020515636A (ja) | 2020-05-28 |
| EP3601229B1 (en) | 2024-11-06 |
| US20200317619A1 (en) | 2020-10-08 |
| MX394818B (es) | 2025-03-24 |
| AU2018238102A2 (en) | 2019-11-07 |
| US11220483B2 (en) | 2022-01-11 |
| KR20190140936A (ko) | 2019-12-20 |
| CN110891938B (zh) | 2023-10-31 |
| RU2019133659A3 (https=) | 2021-07-16 |
| BR112019019868A2 (pt) | 2020-04-22 |
| GB201704714D0 (en) | 2017-05-10 |
| WO2018172727A1 (en) | 2018-09-27 |
| EP3601229A1 (en) | 2020-02-05 |
| MX2019011314A (es) | 2020-01-27 |
| CN110891938A (zh) | 2020-03-17 |
| RU2019133659A (ru) | 2021-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906873B (en) | Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators | |
| ZA201906104B (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| IL271290A (en) | Dihydro-pyrrolo-pyridine derivatives | |
| IL271607A (en) | New azaquinoline histories | |
| IL250823A0 (en) | A new derivative of 6,5-dihydro-h4-benzo[b]thiano-[3,2-d]azepine | |
| HUE065692T2 (hu) | Rapamicin származékok | |
| EP3615083A4 (en) | RAF DEGRADATION CONJUGATES | |
| EP3661513A4 (en) | ORGANOPHOSPHATE DERIVATIVES | |
| IL271935A (en) | NLRP3 modulators | |
| GB201716468D0 (en) | Modulators | |
| IL271665A (en) | benzazapine derivatives | |
| GB201716298D0 (en) | Cake containers | |
| EP3585366A4 (en) | VISUAL CYCLE MODULATORS | |
| ZA201803520B (en) | Indane derivatives as mglur7 modulators | |
| EP3681886A4 (en) | WNT CHANNEL MODULATORS | |
| GB2563095B (en) | Modulators | |
| ZA201606522B (en) | Novel 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds | |
| ZA202000438B (en) | Benzazepine derivatives | |
| HK40022394A (en) | Nlrp3 modulators | |
| GB201702926D0 (en) | Modulators |